Document is current
Any future updates will be listed below
-
Authors
Chalabi Hajkarim, Morteza https://orcid.org/0000-0002-2039-2676
May, Michael
Amin, Amit Dipak https://orcid.org/0000-0002-2613-2082
Jamison, Jacob https://orcid.org/0000-0003-1171-065X
Tagore, Somnath
D’Souza, Edridge https://orcid.org/0000-0003-4664-8163
Caprio, Lindsay https://orcid.org/0000-0003-1370-8684
Walsh, Zachary H.
Fan, Joy Linyue
Zhang, Mingxuan
Shah, Parin
Abuzaid, Sinan https://orcid.org/0009-0000-1629-7556
Michel, Alissa
Dajiang, Sun
Wong, Winston
Shaikh, Neha
Ramaradj, Priyanka
Bakir, Basil
Kluger, Michael D.
Chabot, John
Azizi, Elham https://orcid.org/0000-0001-5059-6971
Hibshoosh, Hanina
Rustgi, Anil K.
Raufi, Alexander G.
Manji, Gulam A. https://orcid.org/0009-0000-7459-6036
Izar, Benjamin https://orcid.org/0000-0003-2379-6702
- License Information
-
More Information
Article History
Received: 13 March 2024
Accepted: 26 August 2025
First Online: 27 October 2025
Competing interests
: G.A.M. receives clinical trial funding from Genentech Roche, Arcus Biosciences, Merck, Plexxikon, Regeneron and BioLineRx, and research funding from Genentech Roche, and is an advisory board member for CEND Pharm, Arcus Biosciences, BioLineRx, Revolution Medicines and Ipsen. B.I. is a consultant for or has received honoraria from Volastra Therapeutics, Johnson & Johnson/Janssen, Novartis, Eisai, AstraZeneca, GSK and Merck and has received research funding to Columbia University from Agenus, Alkermes, Arcus Biosciences, Checkmate Pharmaceuticals, Compugen, Immunocore, Regeneron and Synthekine. B.I. is the scientific founder of Basima Therapeutics, Inc. The other authors declare no competing interests.
